News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Cabaletta Bio received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CABA-201.
Penn spinout Verismo Therapeutics, which focuses on CAR T-cell therapy for solid tumors, has activated its STAR-101 Phase 1 clinical trial at Penn.
PCI’s Carter Caldwell, program director for the Penn Medicine Co-Investment Program, discussed his entrepreneurial career and shared advice for others looking to start businesses.
From CAR-T therapy to the mRNA covid-19 vaccine, the list of Penn-linked FDA approvals has been growing with each passing year.
On May 9th, PCI and the Philadelphia Alliance for Capital and Technologies (PACT) co-hosted the event "The Future of Wearable Technology" at the Pennovation Center as part of Philly Tech Week 2023
SAFELab is a research initiative focused on examining the ways in which youth of color navigate violence on and offline.
Eleven fellows were admitted to the 2023/2024 cohort out of a large application pool.
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co
Penn President Liz Magill awarded the 2023 President’s Innovation Prize toGabriella Daltoso, Sophie Ishiwari, Gabriela Cano, Caroline Amanda Magro, and Tifara Eliana Boyce for their project, Sonura.
Canberra IP will now link to Visible Legacy (VL) Navigator to Search, Navigate, and Connect with context to facilitate and speed up communication with a university licensing office and inventors.